Based on studies suggesting people taking a glucagon-like peptide-1 (GLP-1) could be less likely to develop Alzheimers, Novo Nordisk set up two large trials of its drug, semaglutide sold as the popular diabetes and obesity drugs Ozempic and Wegovy
Overall, GLP-1 receptor agonists may be useful for selected patients with obesity-related KOA, but their use requires careful patient selection, dose titration, adverse-event monitoring, nutritional and functional support, perioperative coordination, and realistic planning for long-term adherence
Therefore, L-carnitine does act as an AhR antagonist, but it minimizes the metabolic effects resulting from activation of hepatic AhR
Characteristics of GLP-1 agonist and control Table 3 highlights important details such as dosage, delivery techniques, control groups, and follow-up periods while summarizing research examining the effects of the GLP-1 agonist ROSE-010